Q-omics provides the consensus-scored USP33 profile across patient tissues and cancer cell-line models. USP33 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, USP33 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, USP33 RNA expression shows 21,125 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where USP33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP33 survival associations across molecular data types. USP33 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP33 RNA expression–survival associations across cancer types. High USP33 expression shows unfavorable associations in LGG and LIHC, but favorable associations in KIRC, SCLC, SKCM and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for USP33 RNA expression.
This table summarizes USP33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for USP33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP33 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, BLCA, CHOL and HNSC. The THCA box plot shows higher USP33 RNA expression in normal versus tumor tissue (log2 FC = −0.619, t-test p < 0.001).
This table shows molecular features associated with USP33 in patient tissues and cancer cell lines. In patient samples, USP33 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, USP33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
